10-K · November 25, 2025
Cencora reported fiscal 2025 revenue of $321.3 billion, up $27.4 billion (9.3%) year-over-year driven by U.S. Healthcare Solutions growth and GLP-1 product volumes; operating income rose 20.8% to $2.63 billion while…
Earnings analysis · 10-Q
COR earnings analysis
Filed May 6, 2026 · Our reading of the company's report
The latest report
Cencora, Inc. reported robust Q2 results for FY26, with revenue of $78.4 billion, a 3.8% increase from the prior year, though slightly missing the consensus estimate of $80.98 billion. The notable E.P.S. of $8.40…
Read full summary
Cencora, Inc. reported robust Q2 results for FY26, with revenue of $78.4 billion, a 3.8% increase from the prior year, though slightly missing the consensus estimate of $80.98 billion. The notable E.P.S. of $8.40 significantly exceeded the expected $4.74, bolstered by a 17.3% increase in gross profit, driven primarily by growth in both U.S. and International Healthcare Solutions segments. Management also raised its adjusted EPS guidance for FY26 from $17.45-$17.75 to $17.65-$17.90, showcasing confidence in future performance despite elevated operating expenses.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $8.4
What stood out
-
Q2 Revenue Grows to $78.4 Billion
Revenue increased by $2.9 billion, or 3.8%, from the prior year, driven by growth in both segments.
-
E.P.S. Significantly Beats Estimates
Reported E.P.S. of $8.40 surpassed the consensus estimate of $4.74.
-
Strong Gross Profit Growth
Gross profit rose by $528.5 million, or 17.3%, signaling improved efficiency and segment performance.
-
U.S. Healthcare Solutions Revenue Up 2.9%
U.S. segment revenue increased by $1.9 billion, primarily driven by specialty product sales.
-
International Segment Revenue Surges
International Healthcare Solutions revenue increased by 13.0%, primarily from growth in Europe.
-
Adjusted EPS Guidance Raised
Management raised the fiscal 2026 EPS guidance to $17.65-$17.90 from a previous $17.45-$17.75.
What to watch
-
Increased Operating Expenses
Total operating expenses rose by $422.1 million, or 20.9%, from the prior year.
-
High Interest Expense
Interest expense increased by $36.5 million, or 35.1%, primarily due to new debt financing for acquisitions.
-
Regulatory Compliance Challenges
Potential risks from regulatory environments have been highlighted as a continuing concern impacting business.
Management's outlook
Adjusted diluted EPS guidance raised from $17.45-$17.75 to $17.65-$17.90 for FY26.
Earlier filings 4
10-Q · January 31, 2024
Cencora reported Q1 revenue of $72,252,833,000 (up 15.0% YoY) and diluted EPS of $2.98 (up $0.65 or 27.9% YoY). Gross profit increased to $2,468,812,000 while operating income rose to $822,875,000; operating cash flow…
10-K · November 21, 2023
Cencora reported fiscal 2023 revenue of $262.173 billion, up $23.6 billion or 9.9% year-over-year, driven primarily by U.S. Healthcare Solutions. Gross profit rose 8.0% to $8.959 billion and diluted EPS increased to…
10-Q · February 1, 2023
AmerisourceBergen reported quarter-over-quarter revenue and EPS growth: revenue of $62,846,832,000 and diluted EPS of $2.33, driven by higher gross profit and net income. Operating cash flow declined to $710,080,000 and…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.